Download PDF
Exp Clin Endocrinol Diabetes 2020; 128(05): 297-302
DOI: 10.1055/a-0723-3295
Article
© Georg Thieme Verlag KG Stuttgart · New York

Altered TEG Parameters Identify Hypercoagulablilty and are of Diagnosis Value for Papillary Thyroid Carcinoma Patients

Songsong Lu
1   Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China
,
Rui Kang
1   Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China
,
Yongchao Wang
1   Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China
2   Department of Clinical Laboratory, China - Japan Friendship Hospital, Beijing, China
,
Mengjie Zhu
1   Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China
,
Lei Zhao
1   Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China
,
Qinzhu Xu
1   Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China
,
Ying Song
1   Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China
,
Chen Liu
1   Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China
› Author Affiliations Funding This work was supported by grants from the Natural Science Foundation of China (81401298).
Further Information

Publication History

received 27 April 2018
revised 06 August 2018

accepted 29 August 2018

Publication Date:
20 September 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Objective The goal of this study was to clarify the changes and clinical significance of thromboelastography (TEG) parameters in papillary thyroid carcinomas and nodular goiters.

Methods 62 nodular goiter (NG) patients and 53 papillary thyroid carcinoma (PTC) patients were included. Coagulation indicators, together with a series of TEG parameters were collected and analyzed, compared with results of 61 healthy controls (HC). Correlation analysis was conducted between routine coagulation indicators and TEG parameters. ROC curves were used to evaluate the potential diagnosis value of the TEG parameters that were altered in papillary thyroid carcinoma patients.

Results APTT and PT in papillary thyroid carcinoma group were statistically significant higher than that in control group (p<0.05). MPV was found to be higher in PTC than NG and healthy controls.

R, K and SP levels were significantly lower in PTC group than that in HC group; Angle, CI and TPI levels were significantly higher in PTC group than that in HC group. Areas under the ROC curve of CI, TPI, and angle were 0.725, 0.714, and 0.687 for distinguishing PTC from HC, 0.662, 0.668 and 0.591 for distinguishing PTC from NG.

Conclusion TEG parameters are altered and indicate hypercoagulablilty status of papillary thyroid carcinoma patients; CI, TPI, and angle could be potential diagnosis indicators for detecting papillary thyroid carcinoma.

Key words

thromboelastography - papillary thyroid carcinoma - nodular goiter - diagnosis

Supplementary Material

 

  • References

  • 1 Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 2009; 115: 3801-3807
    CrossrefPubMedGoogle Scholar
  • 2 Hay ID, Thompson GB, Grant CS. et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26: 879-885
    CrossrefPubMedGoogle Scholar
  • 3 Hegedus L, Bonnema SJ, Bennedbæk FN. Management of simple nodular goiter: Current status and future perspectives. Endocr Rev 2003; 24: 102-132
    CrossrefPubMedGoogle Scholar
  • 4 Rugeri L, Levrat A, David JS. et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5: 289-295
    CrossrefPubMedGoogle Scholar
  • 5 Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 2012; 26: 1-3
    CrossrefPubMedGoogle Scholar
  • 6 Mendez-Angulo JL, Mudge MC, Couto CG. Thromboelastography in equine medicine: Technique and use in clinical research. Equine Vet Educ 2012; 24: 639-649
    CrossrefPubMedGoogle Scholar
  • 7 Schreiber MA. Coagulopathy in the trauma patient. Curr Opin Crit Care 2005; 11: 590-597
    CrossrefPubMedGoogle Scholar
  • 8 Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 5: 116-124
    CrossrefPubMedGoogle Scholar
  • 9 Chandler WL. The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost 1995; 21: 001-006
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Katori N, Tanaka KA, Szlam F. et al. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg 2005; 100: 1781-1785
    CrossrefPubMedGoogle Scholar
  • 11 LI B, JIANG YX, ZHANG Y. Correlation between thromboelastography and conventional blood coagulation monitoring in liver transplantation. J Clin Anesthesiol 2011; 4: 340-342
    PubMedGoogle Scholar
  • 12 Toukh M, Siemens DR, Black A. et al. Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer. Thromb Res 2014; 133: 88-95
    CrossrefPubMedGoogle Scholar
  • 13 Wehrum MJ, Hines JF, Hayes EB. et al. Comparative assessment of hypercoagulability in women with and without gynecologic malignancies using the thromboelastograph coagulation analyzer. Blood Coagul Fibrin 2010; 21: 140-143
    CrossrefPubMedGoogle Scholar
  • 14 Akay OM, Ustuner Z, Canturk Z. et al. Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Med Oncol 2009; 26: 358-364
    CrossrefPubMedGoogle Scholar
  • 15 Franchini M. Hemostatic changes in thyroid diseases: Haemostasis and thrombosis. Hematology 2006; 11: 203-208
    CrossrefPubMedGoogle Scholar
  • 16 Lal G, Brennan TV, Hambleton J. et al. Coagulopathy, marantic endocarditis, and cerebrovascular accidents as paraneoplastic features in medullary thyroid cancer—case report and review of the literature. Thyroid 2003; 13: 601-605
    CrossrefPubMedGoogle Scholar
  • 17 Ordookhani A, Motazedi A, Burman KD. Thrombosis in Thyroid Cancer. Int J Endocrino Metab 2017; 16: e57897
    PubMedGoogle Scholar
  • 18 Nielsen VG, Garol BD, Zelman EA. et al. Hemeoxygenase-1 mediated hypercoagulability in a patient with thyroid cancer. Blood Coagul Fibrin 2013; 24: 663-665
    CrossrefPubMedGoogle Scholar
  • 19 Bowbrick VA, Mikhailidis DP, Stansby G. The use of citrated whole blood in thromboelastography. Anesth Analg 2000; 90: 1086-1088
    CrossrefPubMedGoogle Scholar
  • 20 Traverso CI, Caprini JA, Arcelus JI. The normal thromboelastogram and its interpretation. Semin Thromb Hemost 1995; 21: 7-13
    PubMedGoogle Scholar
  • 21 Donahue SM, Otto CM. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis. J Vet Emerg Crit Care 2005; 15: 9-16
    CrossrefPubMedGoogle Scholar
  • 22 Ågren A, Wikman AT, Holmström M. et al. Thromboelastography (TEG®) compared to conventional coagulation tests in surgical patients –A laboratory evaluation. Scand J Clin Lab Invest 2013; 73: 214-220
    CrossrefPubMedGoogle Scholar
  • 23 Goldenberg NA, Hathaway WE, Jacobson L. et al. A new global assay of coagulation and fibrinolysis. Thromb Res 2005; 116: 345-356
    CrossrefPubMedGoogle Scholar
  • 24 Elbers LP, Moran C, Gerdes VE. et al. The hypercoagulable state in hyperthyroidism is mediated via the thyroid hormone β receptor pathway. Eur J Endocrinol 2016; 174: 755-762
    CrossrefPubMedGoogle Scholar
  • 25 Kim N, Gu JY, Yoo HJ. et al. Contact system activation and high thrombin generation in hyperthyroidism. Eur J Endocrinol 2017; 176: 583-589
    CrossrefPubMedGoogle Scholar
  • 26 Cantürk Z, Çetinarslan B, Tarkun I. et al. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2003; 13: 971-977
    CrossrefPubMedGoogle Scholar
  • 27 Tiede DJ, Tefferi A, Kochhar R. et al. Paraneoplastic cholestasis and hypercoagulability associated with medullary thyroid carcinoma. Resolution with tumor debulking. Cancer 1994; 73: 702-705
    CrossrefPubMedGoogle Scholar
  • 28 Thorson CM, Van Haren RM, Ryan ML. et al. Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection. Surgery 2014; 155: 134-144
    CrossrefPubMedGoogle Scholar